Medibiofarma announces the nomination of a second Development Candidate
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound will start IND enabling studies the second quarter 2019.
To make disease-modifying first-in-class immuno-oncology treatments available to patients suffering from devastating conditions such as cancer
How do we achieve our vision
Medibiofarma focused internal resources on areas where lies the experience of the management team:
- Virtual drug design
- Medicinal Chemistry
- In Vitro Pharmacology
- Intellectual Property
The remaining activities needed for the full compound characterization and the nomination of a development candidate, such as in vivo pharmacology and toxicology and IND-enabling studies are carried out through partnerships with several companies (CROs), Research Centers and Universities.